SOX with or without perioperative camrelizumab in locally advanced gastric cancer
Erman Akkus shared on X:
“Locally advanced gastric cancer.
Perioperative camrelizumab plus low-dose rivoceranib and S-1 and oxaliplatin (SOX) vs. SOX
3xneoadj-surgery-3xadjuvan->up to 1year camre/rivo
pCR: 18.3% vs 5%
Neoadjuvan grade ≥3 trAEs: 34% vs 17%.”
Authors: Chen Li, Yantao Tian, Yanan Zheng, Fei Yuan, Zheng Shi, Lin Yang, Hao Chen, Lixin Jiang, Xixun Wang, Ping Zhao, Benyan Zhang, Zhenqiang Wang, Qun Zhao, Jianhong Dong, Changhong Lian, Sanrong Xu, Aimin Zhang, Zhichao Zheng, Kang Wang, Chengxue Dang, Dan Wu, Jian Chen, Yingwei Xue, Bo Liang, Xiangdong Cheng, Qian Wang, Luchuan Chen, Tao Xia, Heli Liu, Dazhi Xu, Jing Zhuang, Tao Wu, Xi Zhao, Wei Wu, Hongzhi Wang, Junsheng Peng, Zhiguo Hou, Rongrong Zheng, Yuting Chen, Kai Yin, Zhenggang Zhu
More posts featuring Erman Akkus on oncodaily.com
Erman Akkus is a medical oncology fellow at the Ankara University, Faculty of Medicine. Previously, he was an Internal Medicine Resident at the Ankara University, Faculty of Medicine. He was also a Visiting Researcher at the University of Oslo. He completed his education from the Medical University of Vienna.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023